140 related articles for article (PubMed ID: 8895744)
21. p53 alterations but no human papillomavirus infection in preinvasive and advanced squamous esophageal cancer in Italy.
Rugge M; Bovo D; Busatto G; Parenti AR; Fawzy S; Guido M; Ancona E; Ninfo V; Ruol A; Shiao YH
Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):171-6. PubMed ID: 9138659
[TBL] [Abstract][Full Text] [Related]
22. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
23. Association of p53 mutations with metastatic prostate cancer.
Eastham JA; Stapleton AM; Gousse AE; Timme TL; Yang G; Slawin KM; Wheeler TM; Scardino PT; Thompson TC
Clin Cancer Res; 1995 Oct; 1(10):1111-8. PubMed ID: 9815901
[TBL] [Abstract][Full Text] [Related]
24. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
[TBL] [Abstract][Full Text] [Related]
25. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma.
Ribeiro U; Finkelstein SD; Safatle-Ribeiro AV; Landreneau RJ; Clarke MR; Bakker A; Swalsky PA; Gooding WE; Posner MC
Cancer; 1998 Jul; 83(1):7-18. PubMed ID: 9655287
[TBL] [Abstract][Full Text] [Related]
26. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
[TBL] [Abstract][Full Text] [Related]
27. Distant metastases in ovarian cancer: association with p53 mutations.
Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
[TBL] [Abstract][Full Text] [Related]
28. The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients.
Jezersek B; Rudolf Z; Novakovic S
Oncol Rep; 2001; 8(1):77-81. PubMed ID: 11115573
[TBL] [Abstract][Full Text] [Related]
29. [Detection of p53 gene change and serum antibody level in phase II clinical trial of ad p53 gene therapy].
Zhao M; Xiao SW; Yang JX; Zhang SW; Lü YY
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3495-8. PubMed ID: 16686067
[TBL] [Abstract][Full Text] [Related]
30. Mutated p53 in tumors, mutant p53 and p53-specific antibodies in the circulation in patients with gastric cancer.
Maeta M; Saito H; Oka S; Tsujitani S; Ikeguchi M; Kaibara N
J Exp Clin Cancer Res; 2000 Dec; 19(4):489-95. PubMed ID: 11277328
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
[TBL] [Abstract][Full Text] [Related]
32. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer.
Bennett WP; Hollstein MC; He A; Zhu SM; Resau JH; Trump BF; Metcalf RA; Welsh JA; Midgley C; Lane DP
Oncogene; 1991 Oct; 6(10):1779-84. PubMed ID: 1923503
[TBL] [Abstract][Full Text] [Related]
33. p53 Antibodies in the sera of patients with various types of cancer: a review.
Soussi T
Cancer Res; 2000 Apr; 60(7):1777-88. PubMed ID: 10766157
[TBL] [Abstract][Full Text] [Related]
34. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
[TBL] [Abstract][Full Text] [Related]
35. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations.
Mahdavinia M; Bishehsari F; Verginelli F; Cumashi A; Lattanzio R; Sotoudeh M; Ansari R; Semeraro D; Hormazdi M; Fakheri H; Rakhshani N; De Lellis L; Curia MC; Cama A; Piantelli M; Malekzadeh R; Iacobelli S; Mariani-Costantini R
J Cell Physiol; 2008 Aug; 216(2):543-50. PubMed ID: 18330889
[TBL] [Abstract][Full Text] [Related]
36. [Detection of serum anti-p53 antibodies in patients with various types of cancer].
Sakai H
Rinsho Byori; 2002 Jan; 50(1):90-2. PubMed ID: 11871143
[TBL] [Abstract][Full Text] [Related]
37. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
38. [p53 mutations and protein overexpression in primary colorectal cancer and its liver metastasis].
Yang Y; Xia Q; Lian F
Zhonghua Zhong Liu Za Zhi; 1999 Mar; 21(2):114-8. PubMed ID: 11776850
[TBL] [Abstract][Full Text] [Related]
39. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
[TBL] [Abstract][Full Text] [Related]
40. p53 protein expression does not correlate with EBV status in childhood B non-Hodgkin lymphomas.
Klumb CE; Hassan R; Zalcberg IR; Resende LM; Carriço MK; Maia RC
Pediatr Blood Cancer; 2004 Aug; 43(2):115-9. PubMed ID: 15236276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]